These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 20047145)

  • 1. The biological effects of isoform-specific PI3-kinase inhibition.
    Ihle NT; Powis G
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):41-9. PubMed ID: 20047145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease.
    Ito K; Caramori G; Adcock IM
    J Pharmacol Exp Ther; 2007 Apr; 321(1):1-8. PubMed ID: 17021257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?
    Thomas M; Owen C
    Curr Opin Pharmacol; 2008 Jun; 8(3):267-74. PubMed ID: 18394961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for a role for the p110-alpha isoform of PI3K in skeletal function.
    Grey A; Chaussade C; Empson V; Lin JM; Watson M; O'Sullivan S; Rewcastle G; Naot D; Cornish J; Shepherd P
    Biochem Biophys Res Commun; 2010 Jan; 391(1):564-9. PubMed ID: 19931507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphoinositide 3-kinase delta inhibitor as a novel therapeutic agent in asthma.
    Park SJ; Min KH; Lee YC
    Respirology; 2008 Nov; 13(6):764-71. PubMed ID: 18811876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of class II phosphoinositide 3-kinase in cell signalling.
    Falasca M; Maffucci T
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):211-4. PubMed ID: 17371240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat.
    Sturgeon SA; Jones C; Angus JA; Wright CE
    Eur J Pharmacol; 2008 Jun; 587(1-3):209-15. PubMed ID: 18455722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.
    Crowder RJ; Ellis MJ
    Breast Cancer Res; 2005; 7(5):212-4. PubMed ID: 16168140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction.
    Doukas J; Wrasidlo W; Noronha G; Dneprovskaia E; Hood J; Soll R
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):204-6. PubMed ID: 17371238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development.
    Wee S; Lengauer C; Wiederschain D
    Curr Opin Oncol; 2008 Jan; 20(1):77-82. PubMed ID: 18043260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protease-activated receptor-2 stimulates intestinal epithelial chloride transport through activation of PLC and selective PKC isoforms.
    van der Merwe JQ; Moreau F; MacNaughton WK
    Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1258-66. PubMed ID: 19359428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
    Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
    Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
    Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3 kinases in cancer: from oncogene artifact to leading cancer target.
    Zhao JJ; Roberts TM
    Sci STKE; 2006 Dec; 2006(365):pe52. PubMed ID: 17164467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16.
    Billottet C; Grandage VL; Gale RE; Quattropani A; Rommel C; Vanhaesebroeck B; Khwaja A
    Oncogene; 2006 Oct; 25(50):6648-59. PubMed ID: 16702948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreases in phosphoinositide-3-kinase/Akt and extracellular signal-regulated kinase 1/2 signaling activate components of spinal motoneuron death.
    Newbern J; Taylor A; Robinson M; Li L; Milligan CE
    J Neurochem; 2005 Sep; 94(6):1652-65. PubMed ID: 16045454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemically targeting the PI3K family.
    Knight ZA; Shokat KM
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):245-9. PubMed ID: 17371250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taming the PI3K team to hold inflammation and cancer at bay.
    Hirsch E; Ciraolo E; Ghigo A; Costa C
    Pharmacol Ther; 2008 May; 118(2):192-205. PubMed ID: 18420279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.